Conjugated Via Claimed Linking Group, Bond, Or Coupling Agent Patents (Class 424/194.1)
  • Patent number: 11260119
    Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: March 1, 2022
    Assignee: Pfizer Inc.
    Inventors: Robert G. K. Donald, Annaliesa Sybil Anderson, Laurent Oliver Chorro, Jianxin Gu, Jin-Hwan Kim, Srinivas Kodali, Jason Arnold Lotvin, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, Ling Chu, Scott Ellis Lomberk, Karen Kiyoko Takane, Nishith Merchant, Wei Chen
  • Patent number: 11224648
    Abstract: The present disclosure relates to compositions and methods for coupling an antigen to an adjuvant, immunogenic compositions and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: January 18, 2022
    Assignees: Massachusetts Institute of Technology, The Scripps Research Institute
    Inventors: Darrell J. Irvine, Tyson Moyer, William R. Schief
  • Patent number: 11207418
    Abstract: The present disclosure provides a synthetic nanoparticle comprising a peptide nucleic acid (PNA) oligomer conjugated to a lipid, wherein the PNA oligomer noncovalently complexes with an immunomodulatory compound, thereby forming a nanoparticle. The nanoparticles are useful to elicit immune responses and can be used to treat a broad range of cancers and infectious diseases.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: December 28, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Darrell J. Irvine, Eric Dane
  • Patent number: 11135229
    Abstract: Methods, compositions and systems are presented to deliver estradiol benzoate to an animal so as to sterilize the animal. A physiologically acceptable oil or other carrier in a capsule is used to deliver the estradiol benzoate. The estradiol benzoate is delivered intraperitoneally, intramuscularly, or subcutaneously to a companion or livestock animal.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: October 5, 2021
    Assignee: Insigna Inc.
    Inventor: CheMyong Ko
  • Patent number: 10857220
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve coagulase Domains 1-2 and variants thereof.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: December 8, 2020
    Assignee: The University of Chicago
    Inventors: Molly McAdow, Andrea Dedent, Alice Cheng, Carla Emolo, Dominique Missiakas, Olaf Schneewind
  • Patent number: 10751394
    Abstract: The present disclosure relates to neurotoxins and uses thereof. In particular, provided herein are botulinum neurotoxins with altered properties and uses thereof (e.g., research, screening, and therapeutic uses).
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: August 25, 2020
    Assignee: CELLSNAP LLC
    Inventors: Eric A. Johnson, Sabine Pellett, William H. Tepp, Christina Pier, Marite Bradshaw
  • Patent number: 10716839
    Abstract: Longer chain antigenic O-polysaccharide chains for use as a hapten in conjugate vaccines can be produced in a controlled manner using recombinant Gram-negative bacteria that overexpress native or heterologous genes of the wzz family, for example wzzB. Bacteria expressing a chosen wzz gene have modified O-polysaccharide chain lengths, allowing the bacteria to produce lipopolysaccharides having the longer O-polysaccharides. The LPS produced by the bacteria can be hydrolyzed to form core-O-polysaccharide molecules that can be conjugated to a carrier molecule, for example flagellin, to produce a vaccine. The invention also provides recombinant bacteria producing the longer chain O-polysaccharides, the polysaccharide molecules, themselves, conjugated vaccines comprising the O-polysaccharides, pharmaceutical compositions and kits.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: July 21, 2020
    Assignee: University of Maryland, Baltimore
    Inventors: Sharon M. Tennants, Raphael Simon, Myron M. Levine
  • Patent number: 10688162
    Abstract: The present disclosure relates to chimeric neurotoxins and uses thereof. In particular, provided herein are chimeric botulinum neurotoxins with altered properties and uses thereof (e.g., research, screening, and therapeutic uses).
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: June 23, 2020
    Assignee: CELLSNAP LLC
    Inventors: Eric A. Johnson, Sabine Pellett, William H. Tepp, Marite Bradshaw, Christina L. Pier, Joseph T. Barbieri
  • Patent number: 10449211
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5?CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: October 22, 2019
    Assignee: ADURO BIOTECH, INC.
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
  • Patent number: 10363213
    Abstract: The inventive subject matter relates to an immunogenic composition against Campylobacter jejuni comprising isolated capsule polysaccharide from selected pathogenic Campylobacter jejuni strains. The inventive subject matter also relates to methods of using the polysaccharide compositions in inducing an anti-C. jejuni immune response.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: July 30, 2019
    Assignee: The United States of America, as Represented by the Secretary of the Navy
    Inventors: Patricia Guerry, Mario Artur Monteiro
  • Patent number: 10300145
    Abstract: The present disclosure provides a synthetic nanoparticle comprising a peptide nucleic acid (PNA) oligomer conjugated to a lipid, wherein the PNA oligomer noncovalently complexes with an immunomodulatory compound, thereby forming a nanoparticle. The nanoparticles are useful to elicit immune responses and can be used to treat a broad range of cancers and infectious diseases.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: May 28, 2019
    Assignee: Massachusetts Institute of Technology
    Inventors: Darrell J. Irvine, Eric Dane
  • Patent number: 10300135
    Abstract: The present invention refers to new conjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines and formulations containing the same. In addition, the present invention concerns the use of these vaccines in particular for the protection of the human population, and in particular for the protection of the paediatric population from pulmonary and systemic infections due to S. pneumoniae, N. meningitidis, H. influenzae, K. pneumoniae, M. tuberculosis, S. aureus, or from intestinal infections due to S. typhi, V. cholerae and E. coli. The present invention additionally refers to new polyvalent glycoconjugate vaccines for the protection from C. albicans and E. coli systemic and genitourinary infections or for the protection from M. bovis infections in veterinary medicine.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: May 28, 2019
    Assignee: BIOSYNTH S.R.L.
    Inventor: Massimo Porro
  • Patent number: 10195138
    Abstract: Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: February 5, 2019
    Assignee: LABORATORIOS FARMACEUTICOS ROVI, S.A.
    Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
  • Patent number: 10179164
    Abstract: The invention is related to peptide constructs, i.e., polypeptides obtained by linking together two or more peptides based on or derived from different molecules, which are useful in the treatment or prevention of cancer or the treatment of autoimmune diseases and compositions containing same, methods for producing same, and methods for using same; wherein the peptide constructs have the formula P1-x-P2 where P2 is a peptide associated with forms of cancer or an autoimmune condition and P1 is a peptide which will bind to a class of immune cells such as dendritic cells. The peptide construct can cause the maturation of immature dendritic cells to a more mature state. The peptide construct or the more mature dendritic cells can be administered to a subject to a modulate or to initiate an immune response against cancer cells, and can be used with dyes, radioisotopes, or therapeutic agents for detection of the immune target and/or treatment of cancer and autoimmune conditions.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: January 15, 2019
    Assignee: Cel-Sci Corporation
    Inventors: Daniel H. Zimmerman, Eyal Talor, Kenneth Rosenthal
  • Patent number: 10105431
    Abstract: The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: October 23, 2018
    Assignee: Pfizer Inc.
    Inventors: Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
  • Patent number: 10086054
    Abstract: Described herein are synthetic glycan conjugates, immunogenic compositions thereof, vaccines thereof, and kits thereof. The present invention further provides methods of using the synthetic glycan conjugates, immunogenic compositions, or vaccines thereof to treat and/or prevent and/or diagnose proliferative diseases such as cancer. The provided glycan conjugate comprises a carrier and a glycan moiety of Formula (I-i) or Formula (I-ii): (structurally represented).
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: October 2, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Hong-Yang Chuang, Chien-Tai Ren
  • Patent number: 10052373
    Abstract: The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: August 21, 2018
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Dominea Rathwell, Sharavathi Guddehalli Parameswarappa, Subramanian Govindan, Chakkumkal Anish, Claney Lebev Pereira, Peter H. Seeberger, Felix Bröcker
  • Patent number: 9999591
    Abstract: The inventive subject matter relates to an immunogenic composition against Campylobacter jejuni comprising isolated capsule polysaccharide from selected pathogenic Campylobacter jejuni strains. The inventive subject matter also relates to methods of using the polysaccharide compositions in inducing and anti-C. jejuni immune response.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: June 19, 2018
    Assignee: The United States of America as Represented by the Secretary of the Navy
    Inventors: Patricia Guerry, Mario Artur Monteiro
  • Patent number: 9839686
    Abstract: The invention provides a process for preparing a conjugate of a S. aureus type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerising the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidising the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidised saccharide residue; and (c) coupling the oxidised saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: December 12, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano
  • Patent number: 9675681
    Abstract: A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular Streptococcus pneumoniae lysate broth is described. Ultrafiltering and diafiltering a clarified S. pneumoniae lysate followed by pH adjustment to less than 4.5, preferably about 3.5, precipitated at least 98% of the protein in the solution without seriously affecting polysaccharide yield. Furthermore, following ultrafiltration and diafiltration and acidification to a pH of less than 4.5, filtration using activated carbon precipitated at least 90% of remaining protein without seriously affecting polysaccharide yield. Exemplary, non-limiting S. pneumoniae serotypes that can be purified using the shortened process of the invention are 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: June 13, 2017
    Assignee: Wyeth LLC
    Inventors: Yonghui Yuan, Mark Ruppen, Wei-Qiang Sun, Ling Chu, John Simpson, James Patch, Justin Keith Moran, Pamela S. Fink
  • Patent number: 9572875
    Abstract: This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: February 21, 2017
    Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Philip O. Livingston, Govindaswami Ragupathi, Samuel J. Danishefsky
  • Patent number: 9486515
    Abstract: The present application discloses an immunogenic composition comprising at least 2 different N. meningitidis capsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated to a protein carrier(s) wherein the saccharide:protein ratio (w/w) is between 1:2-1:5, and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are conjugated to a protein carrier(s) wherein the saccharide:protein ratio (w/w) is between 5:1-1:1.99.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: November 8, 2016
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
  • Patent number: 9439954
    Abstract: Glucans having exclusively or mainly ?-1,3 linkages are used as immunogens. These comprise ?-1,3-linked glucose residues. Optionally, they may include ?-1,6-linked glucose residues, provided that the ratio of ?-1,3-linked residues to ?-1,6-linked residues is at least 8:1 and/or there are one or more sequences of at least five adjacent non-terminal residues linked to other residues only by ?-1,3 linkages. The glucans will usually be used in conjugated form. A preferred glucan source is curdlan, which may be hydrolyzed to a suitable form prior to conjugation.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: September 13, 2016
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano
  • Patent number: 9345746
    Abstract: The present invention relates to methods and compositions for the treatment and prevention of diarrhea and diarrheal related diseases and disorders in both animals and humans. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders with a vaccine. In still further embodiments, the invention relates to the treatment of constipation using the disclosed methods and compositions.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: May 24, 2016
    Assignee: BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
    Inventor: A. Mahdi Saeed
  • Patent number: 9303013
    Abstract: The present invention relates in part to chemical compounds, and methods for producing these compounds. The compounds may also be incorporated into compositions to enhance quit rates or reduce relapse in smoking cessation and further in treating nicotine-related dependence.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: April 5, 2016
    Assignee: Pfizer Inc.
    Inventors: Janice Ethel Sieser, Robert Alan Singer
  • Patent number: 9289488
    Abstract: The method and constructs disclosed and claimed herein allow to control peptide conformation by modulation of the peptide lipidation pattern, spacer and liposome composition, or via co-administration with small molecules. Accordingly, this technology can be applied to the rational design of liposomal vaccines and for the generation of safer and more efficacious therapies for a range of human disease, in particular those based on misfolded proteins.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: March 22, 2016
    Assignee: AC Immune SA
    Inventors: David Hickman, Maria Pilar Lopez-Deber, Andreas Muhs
  • Patent number: 9187569
    Abstract: The present invention is directed to branched reactive water-soluble polymers comprising at least two polymer arms, such as poly(ethylene glycol), attached to a central aliphatic hydrocarbon core molecule through heteroatom linkages. The branched polymers bear at least one functional group for reacting with a biologically active agent to form a biologically active conjugate. The functional group of the branched polymer can be directly attached to the aliphatic hydrocarbon core or via an intervening linkage, such as a heteroatom, -alkylene-, —O-alkylene-O—, -alkylene-O-alkylene-, -aryl-O—, —O-aryl-, (—O-alkylene-)m, or (-alkylene-O—)m linkage, wherein m is 1-10.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: November 17, 2015
    Assignee: Nektar Therapeutics
    Inventors: Michael D. Bentley, Xuan Zhao, Xiaoming Shen, William D. Battle, III
  • Patent number: 9173936
    Abstract: Provided in some embodiments are compositions comprising a compound having a structure according to Formula A or Formula B: or a pharmaceutically acceptable salt, tautomer or hydrate thereof, where X2 is a bond or linker, X3 is bond or —PO4—, and X1, R1, R2, R3, and n are described herein. Also provided in some embodiments are methods for making and using such compounds and compositions.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: November 3, 2015
    Assignee: Telormedix SA
    Inventors: Roberto Maj, Franco Pattarino, Emanuela Mura, Alcide Barberis
  • Patent number: 9173954
    Abstract: E. coli proteins have been identified that are useful as carrier proteins to improve a response to a polysaccharide immunogen conjugated to such protein. In particular, AcfD precursor protein (orf3526 polypeptide), Flu antigen 43 protein (orf1364 polypeptide), and Sel1 repeat-containing protein (upec-5211 polypeptide) have been shown to be effective. Additionally, these E. coli proteins can enhance the immune response to glucans, particularly fungal glucans.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: November 3, 2015
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Paolo Costantino, Francesco Berti, Francesca Micoli, Anna Kabanova, Laura Serino, Maria Rosaria Romano, Marta Tontini
  • Patent number: 9120848
    Abstract: The invention is a novel chemical coupling methodology for the synthesis of a stable polysaccharide-protein conjugates as the immunogenic component for vaccines. A covalent bond is formed between polysaccharide and protein in the dry state in the absence of water and oxygen. A polysaccharide antigen is covalently linked to the protein by activating the polysaccharide with periodate to introduce aldehyde groups into the polysaccharide, lyophilizing an aqueous mixture of a protein and activated polysaccharide, sealing the dry lyophilized mixture in a vessel under vacuum or inert gas and then incubating the sealed vessel at an elevated temperature.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: September 1, 2015
    Inventor: Harvey Kaplan
  • Patent number: 9115350
    Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: August 25, 2015
    Assignee: Syntaxin Limited
    Inventors: Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
  • Patent number: 9084809
    Abstract: An immunogenic composition, and method of using the composition, composed of a capsule polysaccharide polymer from one or more strains Campylobacter jejuni. The composition is either used alone or is conjugated to a carrier molecule, such as CRM197. An aspect of the invention is that the immunogenic composition induces an immune response without the induction of Gulliam Barre Syndrome.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: July 21, 2015
    Assignee: The United States of America as Represented by the Secretary of the Navy
    Inventors: Patricia Guerry, Shahida Baqar, Mario Artur Monteiro
  • Publication number: 20150110829
    Abstract: Disclosed herein are meningococcal immunogenic conjugates which can elicit immune responses against meningococcal polysaccharides (PS) from groups A, C, W-135, and Y and group B factor H binding protein (fHbp). The disclosed conjugates also exhibit bactericidal activity against meningococcal A, C, W-135, Y, B, and X serogroups. Also disclosed are improved methods for preparing conjugates, such as immunogenic conjugates, including activation of a polysaccharide with a cyanylation agent at about 4° C.
    Type: Application
    Filed: May 23, 2013
    Publication date: April 23, 2015
    Inventors: Che-Hung Robert Lee, Valerian B. Pinto
  • Publication number: 20150110833
    Abstract: Macromolecular imprinted silica particles (“MIP”) in the presence of polymer grafted carbon black are disclosed. The disclosed molecular imprinted beads can detect disease in body fluids. For the silica gel matrix, tetraethyl orthosilicate (TEOS) was used as the backbone monomer and 3-aminopropy/triethoxysilane (APS) as a functional monomer. Carbon black was added to the sol-gel process, yielding black silica particles. Furthermore, sodium dodecyl sulfate (SDS) was used as a structure-directing agent to increase network diffusion of the template. A total of 16 MIPs were synthetized in parallel with variables that evaluate the role of key reactants in the synthesis procedure. Agglomeration tests were performed with all 16 MIPs in the presence of their template, alongside their respective controls using only phosphate buffered saline (“PBS”). Each of the MIPs was evaluated using a novel device capable of simultaneously measuring up to four samples for near infrared transmission.
    Type: Application
    Filed: August 6, 2014
    Publication date: April 23, 2015
    Inventor: Thomas Boland
  • Patent number: 9011870
    Abstract: The invention relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allows the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen-loaded immunogenic carrier complex comprising at least one bifunctional polypeptide attached to an immunogenic carrier, said bifunctional polypeptide comprising a peptidoglycan binding domain (PBD) through which the polypeptide is attached to said carrier, fused to an antigen binding domain (ABD) to which at least one antigen of interest is bound. Also provided is a pharmaceutical (e.g. vaccine) composition comprising an antigen-loaded immunogenic carrier complex of the invention.
    Type: Grant
    Filed: July 20, 2006
    Date of Patent: April 21, 2015
    Assignee: Applied Nanosystems B.V.
    Inventors: Cornelis Johannes Leenhouts, Maarten Leonardus Van Roosmalen, Tjibbe Bosma
  • Patent number: 8993524
    Abstract: The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immune suppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-?) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: March 31, 2015
    Assignee: The Johns Hopkins University
    Inventors: Atul Bedi, Rajani Ravi
  • Publication number: 20150079612
    Abstract: The present invention relates to conjugates of 5-fluorouracil, 5-fluorouracil immunogens, antibodies that bind 5-FU and/or 5-FU conjugated to another molecule, and assays for detecting, quantitating, and monitoring amounts of 5-fluorouracil in a sample such as in blood plasma.
    Type: Application
    Filed: November 30, 2012
    Publication date: March 19, 2015
    Inventors: Paul Q. Hu, Xiaofen Huang, Reid W. Von Borstel
  • Patent number: 8980277
    Abstract: Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH2-A-[-X-L-]n-B—COOH where X is an amino acid sequence, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1. Proteins where each of the n -X- moieties shares sequence identity to each other -X- moiety, the protein is a ‘tandem protein’.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: March 17, 2015
    Assignee: Novartis AG
    Inventor: Mariagrazia Pizza
  • Publication number: 20150071987
    Abstract: In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein. The tumor therapeutic composition or tumor vaccine can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules.
    Type: Application
    Filed: February 1, 2013
    Publication date: March 12, 2015
    Applicant: EMORY UNIVERSITY
    Inventor: Periasamy Selvaraj
  • Patent number: 8974799
    Abstract: The invention provides a process for preparing a conjugate of a S. aureus type 5 or type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerizing the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidizing the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidized saccharide residue; and (c) coupling the oxidized saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: March 10, 2015
    Assignee: Novartis AG
    Inventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano
  • Publication number: 20150064212
    Abstract: Provided are bivalent immunogenic composition against morphine-heroin addiction comprising a carrier protein (“CP”) and a morphinic product, wherein the CP and the morphinic product are connected by a spacer-linker arm having a total molecular size of 16-21 ?, and methods of using the same.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 5, 2015
    Inventors: Benito Anton PALMA, Philippe Leff GELMAN
  • Publication number: 20150044253
    Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ?g.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 12, 2015
    Inventors: Ralph Leon BIEMANS, Dominique BOUTRIAU, Carine CAPIAU, Philippe DENOEL, Pierre DUVIVIER, Jan POOLMAN
  • Patent number: 8951528
    Abstract: The present invention provides IRM conjugates that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety in which the covalent link does not depend on UV irradiation.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: February 10, 2015
    Assignee: 3M Innovative Properties Company
    Inventors: Doris Stoermer, George W. Griesgraber, James D. Mendoza, Jason D. Bonk
  • Publication number: 20150030669
    Abstract: The present invention is directed to carrier systems comprising ether-lipids conjugated to one or more bioactive ligands and exposed on the surface of the carrier system for use in targeted delivery and/or antigen display systems. Optionally one or more further bioactive agents may be encapsulated or embedded within or attached to or adsorbed onto the carrier system. The present invention is further directed to methods of their preparation and their uses in medical applications, such as targeted delivery of bioactive agents to specific tissues or cells and antigen display systems for the study, diagnosis, and treatment of traits, diseases and conditions that respond to said bioactive agents.
    Type: Application
    Filed: March 11, 2013
    Publication date: January 29, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Michael Wilhelm Platscher, Raymond Behrendt, Viola Groehn, Simone Rachel Hoertner, Marco Silvio Passafaro, Finn Bauer
  • Publication number: 20150024001
    Abstract: The present invention addresses the problem of providing an AIDS vaccine whereby mucosal immunity can be induced, the immune system can be defended against breakdown by HIV infection, HIV can be prevented from escaping the immune system by being highly mutable, and rapid HIV infection can be prevented. According to the present invention, provided is an AIDS vaccine comprising a hub antigen and a complex of N2,N6-bis [N2,N6-bis(3,4,5-trihydroxybenzoyl)-L-lysyl]-N-(2-aminoethyl)-L-lys-inamide (TGDK) and fetuin.
    Type: Application
    Filed: August 15, 2012
    Publication date: January 22, 2015
    Applicants: LSIP ,LLC, NATIONAL UNIVERSITY CORPORATION KUMAMMOTO UNIVERSITY
    Inventors: Shogo Misumi, Shozo Shoji, Nobutoki Takamune
  • Publication number: 20150023987
    Abstract: The invention described herein pertains to compounds and conjugates, to compositions, complexes and formulations comprising the compounds and/or conjugates, and to methods of use of the compounds, conjugates and their compositions, complexes and formulations in vaccines and vaccinations and generating immune responses.
    Type: Application
    Filed: January 27, 2012
    Publication date: January 22, 2015
    Applicant: PURDUE RESEARCH FOUNDATION
    Inventor: Lawrence E. Hem
  • Patent number: 8937157
    Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: January 20, 2015
    Assignee: University of Washington
    Inventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
  • Patent number: 8933218
    Abstract: The present application describes a process for conjugating a PNAG which is less than 40% N-acetylated to a carrier protein.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: January 13, 2015
    Assignee: GlaxoSmithKline Biologicals s.a.
    Inventors: Ralph Leon Biemans, Pierre Duvivier, Tomas Maira-Litran
  • Patent number: 8927498
    Abstract: Compounds derived from a transduction complex that enhance memory in mammals and methods of enhancing memory using said compounds are disclosed.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: January 6, 2015
    Assignee: The Translational Genomics Research Institute
    Inventor: Matthew Huentelman
  • Publication number: 20140377302
    Abstract: The invention provides immunogenic polysaccharide protein conjugates comprising capsular polysaccharides from N. Meningitidis serogroup X and methods for preparation thereof. The present invention relates to N. meningitidis X saccharide-carrier protein conjugates prepared by a conjugation reaction. Accordingly, the instant invention relates to multivalent meningococcal polysaccharide protein conjugate composition comprising capsular saccharide from serogroups X and at least one capsular saccharide from A, C, W135 and Y wherein, i) polysaccharides A C W135 X are sized mechanically whereas polysaccharide Y is sized chemically, ii) all saccharide are conjugated to carrier protein via a linker with a cyanylation conjugation chemistry iii) all saccharide to protein ratios in final conjugates are between 0.2-0.6 and iv) at least two different carrier proteins selected from the group consisting of TT, DT and CRM197 are utilized.
    Type: Application
    Filed: January 29, 2013
    Publication date: December 25, 2014
    Inventors: Subhash Vinayak Kapre, Sambhaji Shankar Pisal